Cytokinetics reports Q4 EPS ($1.26), consensus ($1.17)

Reports Q4 revenue $16.9M, consensus $14.26M. “The fourth quarter of 2024 capped off a momentous year for Cytokinetics (CYTK) with progress and achievements across our business. With regulatory submissions on file in the U.S., Europe and China for aficamten and regulatory review activities underway, we are approaching a key inflection point, and our commercial readiness activities are on track to support planned launch activities,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “During recent months, we also started important clinical trials advancing later-stage development programs, setting us up to potentially deliver multiple new medicines to patients over the next several years. With a strong balance sheet and additional access to investment capital, we are well-funded to execute the potential commercial launch of aficamten in 2025, while we advance our pipeline and continue investing in research for the benefit of all stakeholders.”